Matthew Wein
Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary at Metagenomi
Executive
About Matthew Wein
Matthew L. Wein, J.D., is Senior Vice President, Head of Legal, Compliance Officer, and Corporate Secretary at Metagenomi (MGX) since February 2025; he previously served as Vice President of Corporate Legal, Compliance, and Corporate Secretary from February 2024 to February 2025 . He is 54, holds a B.A. from Wesleyan University and a J.D. from USC Law, and is admitted to practice in California and Massachusetts . Prior roles include General Counsel and Corporate Secretary at Mustang Bio (2021–2023), Senior Director roles in global strategy and alliance management at Sanofi (2016–2021), and Senior Counsel at Amgen (2002–2016); he began his career as an associate at Arter & Haden LLP (1999–2002) . MGX’s recent operating context: quarterly revenues and EBITDA over the last year are shown below.
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|
| Revenues (USD) | $9,614,000* | $4,127,000 | $8,513,000 | $8,659,000 |
| EBITDA (USD) | -$19,162,000* | -$26,462,000* | -$19,652,000* | -$21,515,000* |
Values marked with an asterisk were retrieved from S&P Global.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Mustang Bio (Nasdaq: MBIO) | General Counsel & Corporate Secretary | 2021–2023 | Led legal and governance through public-company operations . |
| Sanofi | Senior Director, Global Strategy & Alliance Management | 2016–2021 | Managed alliances and global strategy across therapeutics . |
| Amgen (Nasdaq: AMGN) | Senior Counsel | 2002–2016 | Supported major biotech legal matters and transactions . |
| Arter & Haden LLP | Associate Attorney | 1999–2002 | Foundational corporate and securities practice experience . |
External Roles
| Credential | Jurisdiction | Notes |
|---|---|---|
| Bar Admission | California; Massachusetts | Active admissions disclosed in company filings . |
Fixed Compensation
- MGX discloses executive compensation for NEOs only (CEO, President/COO, CFO) as an emerging growth/smaller reporting company; Wein is not a NEO, so his base salary and target bonus are not disclosed .
Performance Compensation
| Plan | Metrics & Structure | Notes |
|---|---|---|
| Senior Executive Cash Incentive Bonus Plan | Corporate and individual targets tied to financial and operational measures set by the compensation committee; payouts based on achievement vs. targets . | Applies to executives per plan; Wein-specific targets not disclosed . |
| Compensation Recovery (Clawback) | Restatement-triggered clawback of incentive compensation paid to executive officers based on performance targets; adopted Jan 26, 2024 (effective Jan 5, 2024) . | Enhances pay-for-performance discipline . |
Equity Ownership & Alignment
- Beneficial ownership: On his initial Form 3 (Feb 8, 2024), Wein reported no beneficial ownership of MGX securities .
- Grants and vesting schedules (per Form 4s):
- RSUs: 25% vest on March 5, 2025, with remaining 75% vesting in 12 equal quarterly installments thereafter, subject to continued service .
- Stock Options: 25% vest and become exercisable on February 1, 2025, with remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service .
- Multiple Form 4s were filed in March, April, and June 2025, indicating transactions/holdings updates and 10b5-1 plan usage box checked on filings .
| Award Type | Key Dates | Vesting Detail | Source |
|---|---|---|---|
| RSUs | Initial vest: Mar 5, 2025 | 25% on Mar 5, 2025; remaining 75% in 12 quarterly tranches | |
| Options | Initial vest: Feb 1, 2025 | 25% on Feb 1, 2025; remaining 75% monthly over 36 months | |
| Section 16 Activity | Mar 7, Apr 3, Jun 9, 2025 | Form 4 filings; 10b5-1 plan checkbox indicated |
- Hedging and pledging: MGX’s insider trading policy prohibits short sales, derivative/hedging transactions, and pledging of company securities by executive officers, directors, and employees—mitigating misalignment/forced selling risks .
- Rule 10b5-1 policy: MGX permits 10b5-1 trading plans; Wein serves as Compliance Officer administering the insider trading policy .
Employment Terms
- Role and tenure: SVP, Head of Legal; Compliance Officer; Corporate Secretary since Feb 2025; VP-level from Feb 2024 .
- Severance & Change in Control (CIC) Policy: MGX’s Executive Severance and CIC Policy covers NEOs and certain other executives; tiered benefits include salary continuation (or lump sum in CIC), pro‑rated target bonus, health premium equivalents, and full acceleration of time‑based equity in CIC (performance equity treated per award terms) .
- Outside CIC: CEO 12 months; Tier 2 (other senior officers) 9 months; Tier 3 (generally VPs+) 6 months salary and health contribution equivalents, paid over the applicable period .
- Within CIC period: CEO 18 months; Tier 2 12 months; Tier 3 10 months base salary lump sum, plus 100% target bonus pro‑rated, health contribution equivalents, and full acceleration of time‑based equity .
- Tax treatment: Potential 280G/4999 excise exposure with cut‑down if beneficial to the executive .
- Non‑compete/Non‑solicit: MGX uses Employee Invention Assignment and Confidentiality Agreements with non‑solicitation provisions for executives; specific terms for Wein were not individually disclosed .
Investment Implications
- Insider selling pressure: Quarterly RSU vesting (beginning March 5, 2025) and monthly option vesting (beginning February 1, 2025) create predictable potential supply events; use of 10b5-1 plans suggests pre‑scheduled trades rather than discretionary selling, moderating signaling value of transactions .
- Alignment and governance: Hedging/pledging bans, clawback policy, and compliance oversight (Wein as Compliance Officer) support strong alignment and disciplined trading behavior .
- Retention and CIC dynamics: Participation in the tiered Severance/CIC framework (for eligible executives) would enhance retention, but CIC triggers include full acceleration of time‑based equity—potentially increasing executive willingness to support strategic transactions when value is realized .
- Data gaps: As a non‑NEO, Wein’s cash compensation and ownership totals are not disclosed; monitoring Form 4s and any future 8‑K Item 5.02 filings is essential for updates to equity grants and employment terms .
Citations: